First RSV epidemic with nirsevimab. Older children than previous epidemics, even when hospitalized

J Med Virol. 2024 Feb;96(2):e29483. doi: 10.1002/jmv.29483.

Authors

Aymeric Cantais¹, Nadine Annino¹, Charlotte Thuiller¹, Louise Tripodi¹, Philippine Cesana¹, Eloise Seigle-Ferrand¹, Franck Zekre², Sylvie Pillet³, Bruno Pozzetto³

Affiliations

¹ Paediatric Emergency Department, University Hospital of Saint-Étienne, Saint-Étienne, France.
² Paediatric Department, University Hospital of Saint-Étienne, Saint-Étienne, France.
³ Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France.

PMID: 38375933
DOI: 10.1002/jmv.29483

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Antibodies, Monoclonal, Humanized / therapeutic use
Child
Epidemics*
Humans
Infant
Respiratory Syncytial Virus Infections* / epidemiology
Respiratory Syncytial Virus, Human*

Substances

nirsevimab
Antibodies, Monoclonal, Humanized